Germany Lung Cancer Therapeutics Market Report 2022 to 2030

Germany Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Germany Lung Cancer Therapeutics Market will reach a value of $1.78 Bn from $1.09 Bn in 2022, growing at a CAGR of 6.3% during 2022-2030. The Lung Cancer Therapeutics Market in Germany is dominated by a few domestic pharmaceutical companies such as Boehringer Ingelheim, Merck KGaA, and Bayer. The Lung Cancer Therapeutics Market in Germany is segmented into different types of cancer and different therapy type. Some of the major factors affecting the German lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10DEPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Vishwa Modhia

Buy Now

Germany Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Germany Lung Cancer Therapeutics market will reach a value of $1.78 Bn from $1.09 Bn in 2022, growing at a CAGR of 6.3% during 2022-30.

Germany is a developed, high-income country in the centre of Western Europe. The prevalence of lung cancer, the availability of numerous treatment options, and the country's healthcare policies and regulations all influence the consumption of lung cancer therapies in Germany.

Lung cancer is one of the most prevalent types of cancer in Germany, accounting for around 13% of all cancer incidences, according to a German Cancer Society study. As a result, the consumption of lung cancer therapies in Germany is relatively high. Lung cancer fatalities in Germany reached 46,560 in 2020, accounting for 6.64 per cent of overall deaths, according to the most recent WHO data. The age-adjusted death rate is 24.77 per 100,000 people. Germany is 27^th in the world. Germany's government spends 12.8 % of its GDP on healthcare.

Germany Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Cancer is the second leading cause of death, accounting for 25% of all deaths. In 2018, 57,000 new cases of lung cancer were diagnosed. The median age at cancer diagnosis is 69 (women) and 70 years (men), respectively, 52 % of all patients come with stage IV. After an initiative from the DKG, dedicated lung cancer centres have been built since 2009. In Germany, the German National Cancer Plan recognises organ cancer centres (such as lung cancer centres), oncology centres, and comprehensive cancer centres for general oncologic care. Germany has low structural unemployment and a well-developed apprenticeship programme. These aspects could boost Germany's Lung Cancer Therapeutics market.

Market Restraints

Lung cancer is a major cause of illness, mortality, and socioeconomic expenses in Germany. However, curbs on advertising and education initiatives have resulted in a significant decline in youth smoking during the last few decades. Patients' care is highly standardised and adheres to consensus-based national criteria. Despite immigration, the German labour force is predicted to shrink starting in 2020. These factors may deter new entrants into the Germany Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Boehringer Ingelheim: Boehringer Ingelheim is a German multinational pharmaceutical company that produces several drugs for the treatment of lung cancer, including Gilotrif and Ofev
Merck KGaA: Merck KGaA is a German multinational pharmaceutical and chemical company that produces several drugs for the treatment of lung cancer, including Erbitux
Bayer: Bayer is a German multinational pharmaceutical and life sciences company that produces several drugs for the treatment of lung cancer, including Nexavar and Stivarga
Medigene AG: Medigene AG is a German biotechnology company that is focused on the development of personalized immunotherapies for the treatment of cancer, including lung cancer
BioNTech: BioNTech is a German biotechnology company that has gained international recognition for its development of the COVID-19 vaccine. They are also involved in the development of personalized immunotherapies for the treatment of cancer, including lung cancer

Recent Notable Updates

January 2023: Today, Boehringer Ingelheim and 3T Biosciences announced a strategic collaboration and licencing agreement to research and develop next-generation cancer medicines to address significant unmet patient needs. The collaboration will combine 3T Biosciences' best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim's two-pronged research strategy that combines cancer cell-directed and immune cell-targeting compounds, bolstering the company's pipeline.

Healthcare Policies and Reimbursement Scenarios

Lung cancer therapeutics in Germany are regulated and reimbursed by several entities, including the Federal Institute for Drugs and Medical Devices (BfArM), the Institute for Quality and Efficiency in Health Care (IQWiG), and the German healthcare system. The BfArM is responsible for the approval and regulation of lung cancer therapeutics in Germany. IQWiG evaluates the cost-effectiveness of lung cancer therapeutics and makes recommendations on whether they should be reimbursed by the German healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.